Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.

Check Now!
SALE Plaque Psoriasis Market
Plaque Psoriasis Market
Plaque Psoriasis - Market Insight, Epidemiology And Market Forecast - 2032
  • Published Date : Jul 2023

  • Pages : 200

  • Delivery Time : 7-10 Business Days

  • Region : United States, EU5, Japan

Plaque Psoriasis Market

  • The Plaque Psoriasis market is expected to strengthen as awareness of the disease increases and more effective interventions are being developed.
  • The leading Plaque Psoriasis Companies working in the market include Dermavant Sciences GmbH, IQVIA Biotech, UCB Biopharma SRL, Parexel, Samsung Bioepis Co., Ltd, Durect, Astellas, Biogen, Dow Pharmaceutical Sciences, Shire, Zalicus, AbbVie, Santalis Pharmaceuticals Inc, Maruho Co Ltd, Novartis, AstraZeneca, Pfizer, and others

Request for unlocking the CAGR of Plaque Psoriasis Market

DelveInsight's "Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Plaque Psoriasis, historical and forecasted epidemiology as well as the Plaque Psoriasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Plaque Psoriasis market report provides current treatment practices, emerging drugs, Plaque Psoriasis market share of the individual therapies, current and forecasted Plaque Psoriasis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Plaque Psoriasis treatment practice/algorithm, market drivers, market barriers and Plaque Psoriasis unmet needs to curate the best of the opportunities and assesses the underlying potential of the Plaque Psoriasis market.

Study Period

2019 to 2032

Forecast Period

2023-2032

Geographies Covered

The US, EU4 (Germany, France, Italy, and Spain) and UK, and Japan

Plaque Psoriasis Market

  • Total Market Size
  • Market Size by Therapies
  • Market Size by Class

Plaque Psoriasis Market Size

Request Market Size to Know

Plaque Psoriasis Companies

  • Dermavant Sciences GmbH
  • IQVIA Biotech
  • UCB Biopharma SRL
  • Parexel
  • Samsung Bioepis Co. Ltd.
  • Durect
  • Astellas
  • Biogen
  • Dow Pharmaceutical Sciences
  • Shire
  • Zalicus
  • AbbVie
  • Santalis Pharmaceuticals Inc
  • Maruho Co Ltd
  • Novartis
  • AstraZeneca
  • Pfizer

Plaque Psoriasis Treatment Market

The Plaque Psoriasis Treatment market is a dynamic and essential segment within the pharmaceutical and healthcare industry. Plaque psoriasis is a chronic autoimmune skin condition characterized by red, itchy, and scaly patches that can significantly impact a patient's quality of life. The market for treating plaque psoriasis has witnessed remarkable growth in recent years, fueled by advancements in medical research and the development of innovative therapies.

Plaque Psoriasis Diagnosis

Plaque psoriasis diagnosis involves a thorough evaluation by a healthcare professional, typically a dermatologist. The process begins with a detailed medical history, where the doctor will inquire about the patient's symptoms, their duration, and any triggers that may exacerbate the condition. This segment of the report covers the detailed diagnostic methods or tests for Plaque Psoriasis.

Plaque Psoriasis Treatment

The most common approaches is topical treatments, which involve applying creams, ointments, or gels directly to the affected areas. These topical medications often contain corticosteroids, retinoid, or vitamin D analogs, which help reduce inflammation and control the excessive skin cell growth associated with psoriasis. It covers the details of conventional and current medical therapies available in the Plaque Psoriasis market for the treatment of the condition. It also provides Plaque Psoriasis treatment algorithms and guidelines in the United States, Europe, and Japan.

Recent Developmental Activities in the Plaque Psoriasis Treatment Landscape

  • On May 2023, Samsung Bioepis Co Ltd announced a study of phase 4 clinical trials for Humira (Adalimumab) and SB5 (Adalimumab Biosimilar). This study is referred to as Phase IV, and it is designed as a randomized, double-blind, parallel-group, multiple-dose, active comparator, multicenter clinical trial. Its primary objective is to assess and compare the pharmacokinetics, efficacy, safety, and immunogenicity of SB5 and Humira in individuals diagnosed with moderate to severe chronic plaque psoriasis.
  • On June 2023, Affibody announced a study of phase 2 clinical trials for ABY-035. The Core study spans three distinct periods: Induction (Week 0-12), Optimization (Week 12-24), and Individualization (Week 24-52), each serving a specific purpose in the research. Throughout this study, participants will be carefully monitored and their responses will be analyzed to draw valuable conclusions.

Plaque Psoriasis Epidemiology

The Plaque Psoriasis epidemiology section provides insights about the historical and current Plaque Psoriasis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Plaque Psoriasis market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Plaque Psoriasis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Plaque Psoriasis Epidemiology

The epidemiology segment also provides the Plaque Psoriasis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Plaque Psoriasis Drug Chapters

The drug chapter segment of the Plaque Psoriasis report encloses the detailed analysis of Plaque Psoriasis marketed drugs and late-stage (Phase-III and Phase-II) Plaque Psoriasis pipeline drugs. It also helps to understand the Plaque Psoriasis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Plaque Psoriasis Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Plaque Psoriasis treatment.

Plaque Psoriasis Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Plaque Psoriasis treatment.

Plaque Psoriasis Market Outlook

The Plaque Psoriasis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Plaque Psoriasis market trends by analyzing the impact of current Plaque Psoriasis therapies on the market, Plaque Psoriasis unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Plaque Psoriasis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Plaque Psoriasis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Plaque Psoriasis market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Plaque Psoriasis market in 7MM.

The United States Market Outlook

This section provides the total Plaque Psoriasis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Plaque Psoriasis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Plaque Psoriasis market size and market size by therapies in Japan is also mentioned.

Plaque Psoriasis Drugs Uptake

This section focuses on the rate of uptake of the potential Plaque Psoriasis drugs recently launched in the Plaque Psoriasis market or expected to get launched in the market during the study period 2019-2032. The analysis covers Plaque Psoriasis market uptake by drugs; patient uptake by therapies; and sales of each drug.

Plaque Psoriasis Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new plaque psoriasis drugs, and allow the comparison of the drugs on the basis of Plaque Psoriasis market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Plaque Psoriasis Pipeline Development Activities

The Plaque Psoriasis report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Plaque Psoriasis companies involved in developing targeted therapeutics.

Pipeline Development Activities

The Plaque Psoriasis report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Plaque Psoriasis emerging therapies.

Reimbursement Scenario in Plaque Psoriasis

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Plaque Psoriasis market trends, we take KOLs and SMEs ' opinion working in the Plaque Psoriasis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Plaque Psoriasis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the Plaque Psoriasis unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Plaque Psoriasis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Plaque Psoriasis Market Report Scope

  • The report covers the descriptive overview of Plaque Psoriasis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Plaque Psoriasis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Plaque Psoriasis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Plaque Psoriasis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The patient-based Plaque Psoriasis market forecasting report provides an edge while developing business strategies, by understanding trends shaping and driving the global Plaque Psoriasis market

Plaque Psoriasis Market Report Highlights

  • In the coming years, the Plaque Psoriasis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The Plaque Psoriasis companies and academics are working to assess challenges and seek opportunities that could influence Plaque Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Plaque Psoriasis companies are involved in developing therapies for Plaque Psoriasis. The launch of emerging therapies will significantly impact the Plaque Psoriasis market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Plaque Psoriasis
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed Plaque Psoriasis clinical trials profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Plaque Psoriasis Market Report Insights

  • Patient-based Plaque Psoriasis Market Forecasting
  • Therapeutic Approaches
  • Plaque Psoriasis Pipeline Analysis
  • Plaque Psoriasis Market Size and Trends
  • Plaque Psoriasis Market Opportunities
  • Impact of upcoming Plaque Psoriasis Therapies

Plaque Psoriasis Market Report Key Strengths

  • 10 Years Plaque Psoriasis Market Forecast
  • 7MM Coverage
  • Plaque Psoriasis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Plaque Psoriasis Market Report Assessment

  • Current Plaque Psoriasis Treatment Market Practices
  • Plaque Psoriasis Unmet Needs
  • Plaque Psoriasis Pipeline Product Profiles
  • Plaque Psoriasis Market Attractiveness
  • Plaque Psoriasis Market Drivers
  • Plaque Psoriasis Market Barriers

Key Questions

Market Insights:

  • What was the Plaque Psoriasis drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the total Plaque Psoriasis market size as well as market size by therapies across the 7MM during the forecast period (2023-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Plaque Psoriasis market size during the forecast period (2023-2032)?
  • At what CAGR, the Plaque Psoriasis market is expected to grow by 7MM during the forecast period (2023-2032)?
  • What would be the Plaque Psoriasis market outlook across the 7MM during the forecast period (2023-2032)?
  • What would be the Plaque Psoriasis market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of the Plaque Psoriasis?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Plaque Psoriasis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Plaque Psoriasis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Plaque Psoriasis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Plaque Psoriasis during the forecast period (2023-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2023-2032)?

Current Plaque Psoriasis Treatment Market Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Plaque Psoriasis treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of Plaque Psoriasis in the USA, Europe, and Japan?
  • What are the Plaque Psoriasis marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Plaque Psoriasis?
  • How many therapies are in-development by each company for Plaque Psoriasis treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Plaque Psoriasis treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Plaque Psoriasis therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Plaque Psoriasis and their status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for Plaque Psoriasis?
  • What are the global historical and forecasted market of Plaque Psoriasis?

Reasons to buy

  • The patient-based Plaque Psoriasis market forecasting report will help in developing business strategies by understanding trends shaping and driving the Plaque Psoriasis market
  • To understand the future market competition in the Plaque Psoriasis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Plaque Psoriasis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Plaque Psoriasis market
  • To understand the future market competition in the Plaque Psoriasis market

1. Key Insights

2. Executive Summary of Plaque Psoriasis

3. Competitive Intelligence Analysis for Plaque Psoriasis

4. Plaque Psoriasis: Market Overview at a Glance

4.1. Plaque Psoriasis Total Market Share (%) Distribution in 2019

4.2. Plaque Psoriasis Total Market Share (%) Distribution in 2032

5. Plaque Psoriasis: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Plaque Psoriasis Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Plaque Psoriasis Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.4.1. Plaque Psoriasis Epidemiology Scenario in the United States (2019-2032)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Plaque Psoriasis Epidemiology Scenario in Germany (2019-2032)

7.5.2. France Epidemiology

7.5.2.1. Plaque Psoriasis Epidemiology Scenario in France (2019-2032)

7.5.3. Italy Epidemiology

7.5.3.1. Plaque Psoriasis Epidemiology Scenario in Italy (2019-2032)

7.5.4. Spain Epidemiology

7.5.4.1. Plaque Psoriasis Epidemiology Scenario in Spain (2019-2032)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Plaque Psoriasis Epidemiology Scenario in the United Kingdom (2019-2032)

7.5.6. Japan Epidemiology

7.5.6.1. Plaque Psoriasis Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Plaque Psoriasis Treatment and Management

8.2. Plaque Psoriasis Treatment Algorithm

9. Plaque Psoriasis Unmet Needs

10. Key Endpoints of Plaque Psoriasis Treatment

11. Plaque Psoriasis Marketed Products

11.1. List of Plaque Psoriasis Marketed Drugs in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Plaque Psoriasis Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Plaque Psoriasis: Seven Major Market Analysis

13.1. Key Findings

13.2. Plaque Psoriasis Market Size in 7MM

13.3. Plaque Psoriasis Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Plaque Psoriasis Total Market Size in the United States

15.1.2. Plaque Psoriasis Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Plaque Psoriasis Total Market Size in Germany

15.3.2. Plaque Psoriasis Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Plaque Psoriasis Total Market Size in France

15.4.2. Plaque Psoriasis Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Plaque Psoriasis Total Market Size in Italy

15.5.2. Plaque Psoriasis Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Plaque Psoriasis Total Market Size in Spain

15.6.2. Plaque Psoriasis Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Plaque Psoriasis Total Market Size in the United Kingdom

15.7.2. Plaque Psoriasis Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Plaque Psoriasis Total Market Size in Japan

15.8.3. Plaque Psoriasis Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Plaque Psoriasis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary.

List of Tables:

  • Table 1: 7MM Plaque Psoriasis Epidemiology (2019-2032)
  • Table 2: 7MM Plaque Psoriasis Diagnosed and Treatable Cases (2019-2032)
  • Table 3: Plaque Psoriasis Epidemiology in the United States (2019-2032)
  • Table 4: Plaque Psoriasis Diagnosed and Treatable Cases in the United States (2019-2032)
  • Table 5: Plaque Psoriasis Epidemiology in Germany (2019-2032)
  • Table 6: Plaque Psoriasis Diagnosed and Treatable Cases in Germany (2019-2032)
  • Table 7: Plaque Psoriasis Epidemiology in France (2019-2032)
  • Table 8: Plaque Psoriasis Diagnosed and Treatable Cases in France (2019-2032)
  • Table 9: Plaque Psoriasis Epidemiology in Italy (2019-2032)
  • Table 10: Plaque Psoriasis Diagnosed and Treatable Cases in Italy (2019-2032)
  • Table 11: Plaque Psoriasis Epidemiology in Spain (2019-2032)
  • Table 12: Plaque Psoriasis Diagnosed and Treatable Cases in Spain (2019-2032)
  • Table 13: Plaque Psoriasis Epidemiology in the UK (2019-2032)
  • Table 14: Plaque Psoriasis Diagnosed and Treatable Cases in the UK (2019-2032)
  • Table 15: Plaque Psoriasis Epidemiology in Japan (2019-2032)
  • Table 16: Plaque Psoriasis Diagnosed and Treatable Cases in Japan (2019-2032)
  • Table 17: Drug Name, Clinical Trials by Recruitment status
  • Table 18: Drug Name, Clinical Trials by Zone
  • Table 19: Total Seven Major Market Size in USD, Million (2019-2032)
  • Table 20: Region-wise Market Size in USD, Million (2019-2032)
  • Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
  • Table 22: United States Market Size in USD, Million (2019-2032)
  • Table 23: United States Market Size by Therapy in USD, Million (2019-2032)
  • Table 24: Germany Market Size in USD, Million (2019-2032)
  • Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)
  • Table 26: France Market Size in USD, Million (2019-2032)
  • Table 27: France Market Size by Therapy in USD, Million (2019-2032)
  • Table 28: Italy Market Size in USD, Million (2019-2032)
  • Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)
  • Table 30: Spain Market Size in USD, Million (2019-2032)
  • Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)
  • Table 32: United Kingdom Market Size in USD, Million (2019-2032)
  • Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
  • Table 34: Japan Market Size in USD, Million (2019-2032)
  • Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)
  • *The list of tables is not exhaustive; the final content may vary

List of Figures:

  • Figure 1: 7MM Plaque Psoriasis Epidemiology (2019-2032)
  • Figure 2: 7MM Plaque Psoriasis Diagnosed and Treatable Cases (2019-2032)
  • Figure 3: Plaque Psoriasis Epidemiology in the United States (2019-2032)
  • Figure 4: Plaque Psoriasis Diagnosed and Treatable Cases in the United States (2019-2032)
  • Figure 5: Plaque Psoriasis Epidemiology in Germany (2019-2032)
  • Figure 6: Plaque Psoriasis Diagnosed and Treatable Cases in Germany (2019-2032)
  • Figure 7: Plaque Psoriasis Epidemiology in France (2019-2032)
  • Figure 8: Plaque Psoriasis Diagnosed and Treatable Cases in France (2019-2032)
  • Figure 9: Plaque Psoriasis Epidemiology in Italy (2019-2032)
  • Figure 10: Plaque Psoriasis Diagnosed and Treatable Cases in Italy (2019-2032)
  • Figure 11: Plaque Psoriasis Epidemiology in Spain (2019-2032)
  • Figure 12: Plaque Psoriasis Diagnosed and Treatable Cases in Spain (2019-2032)
  • Figure 13: Plaque Psoriasis Epidemiology in the UK (2019-2032)
  • Figure 14: Plaque Psoriasis Diagnosed and Treatable Cases in the UK (2019-2032)
  • Figure 15: Plaque Psoriasis Epidemiology in Japan (2019-2032)
  • Figure 16: Plaque Psoriasis Diagnosed and Treatable Cases in Japan (2019-2032)
  • Figure 17: Drug Name, Clinical Trials by Recruitment status
  • Figure 18: Drug Name, Clinical Trials by Zone
  • Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)
  • Figure 20: Region-wise Market Size in USD, Million (2019-2032)
  • Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
  • Figure 22: United States Market Size in USD, Million (2019-2032)
  • Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)
  • Figure 24: Germany Market Size in USD, Million (2019-2032)
  • Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)
  • Figure 26: France Market Size in USD, Million (2019-2032)
  • Figure 27: France Market Size by Therapy in USD, Million (2019-2032)
  • Figure 28: Italy Market Size in USD, Million (2019-2032)
  • Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)
  • Figure 30: Spain Market Size in USD, Million (2019-2032)
  • Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)
  • Figure 32: United Kingdom Market Size in USD, Million (2019-2032)
  • Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
  • Figure 34: Japan Market Size in USD, Million (2019-2032)
  • Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)
  • *The list of figures is not exhaustive; the final content may vary

List of Companies:

    • Dermavant Sciences GmbH
    • IQVIA Biotech
    • UCB Biopharma SRL
    • Parexel
    • Samsung Bioepis Co., Ltd.
    • Durect
    • Astellas
    • Biogen
    • Dow Pharmaceutical Sciences
    • Shire
    • Zalicus
    • AbbVie
    • Santalis Pharmaceuticals Inc
    • Maruho Co Ltd
    • Novartis
    • AstraZeneca
    • Pfizer

Frequently Asked Questions

Plaque psoriasis is a chronic and non-contagious skin condition characterized by the formation of red, raised patches covered with silvery-white scales.

The study period of the report is 2019-2032

Dermavant Sciences GmbH, IQVIA Biotech, UCB Biopharma SRL, Parexel, Samsung Bioepis Co., Ltd, Durect, Astellas, Biogen, Dow Pharmaceutical Sciences, Shire, Zalicus, AbbVie, Santalis Pharmaceuticals Inc, Maruho Co Ltd, Novartis, AstraZeneca, Pfizer, and others

With recently launched drug and anticipated approval of therapies during the forecast period, it is expected to drive the market with a significant CAGR.

Related Reports

Chronic Plaque Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Chronic Plaque Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Plaque Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Plaque Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Tags:

loader

Request Sample

View Pricing